Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
HIMS reported a proposed resale under Form 144 for Class A common stock, showing 97,289 shares listed in the filing as the securities to be sold. The filing notes these shares relate to restricted stock vesting (03/15/2026) and are listed with Fidelity Brokerage Services.
The filing also discloses a prior sale: 13,750 Class A shares were sold on 12/17/2025 for $504,762.50, reported under "Securities Sold During The Past 3 Months." The transaction is identified as a compensation-related disposition in the filing.
Becklund Irene reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that PAO Irene Becklund received a grant of 62,076 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Class A Common Stock. These RSUs vest over four years in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, beginning on June 15, 2026, subject to continued service. Following this award, Becklund holds rights relating to 62,076 underlying shares of Class A Common Stock, reflecting a compensation-related equity grant rather than any open-market stock purchase or sale.
Chi Michael reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Operating Officer Michael Chi received a grant of 376,222 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A common stock, making this a stock-based compensation award rather than a market purchase.
The RSUs are subject to a service-based vesting schedule over four years, vesting in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, with the first vesting date on June 15, 2026. Following this grant, Chi holds 376,222 RSUs directly.
Autor Deborah M. reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Policy Officer Deborah M. Autor received a grant of 526,711 Restricted Stock Units (RSUs), each representing a right to receive one share of Class A common stock. The RSUs vest over four years in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, beginning on March 15, 2026. Following this award, she holds 526,711 RSUs directly.
Carroll Patrick Harrison reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Medical Officer Patrick Harrison Carroll received a grant of 150,489 Restricted Stock Units. Each RSU represents a contingent right to one share of Class A Common Stock. The award vests over four years in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, beginning on June 15, 2026, subject to continued service.
Boughton Soleil reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Legal Officer Soleil Boughton received a grant of 188,111 Restricted Stock Units (RSUs), each representing a right to one share of Class A common stock. The RSUs vest over four years in substantially equal quarterly installments, beginning on June 15, 2026, with vesting dates on March 15, June 15, September 15 and December 15.
Elshenawy Mohamed reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that CTO Mohamed Elshenawy received a grant of 376,222 Restricted Stock Units, each representing a contingent right to receive one share of Class A Common Stock. This compensation award was recorded at a price of $0.00 per unit.
The RSUs are subject to a service-based vesting schedule over four years, vesting in substantially equal quarterly installments on March 15, June 15, September 15 and December 15. The first vesting date is June 15, 2026, and continued service is required for vesting. After this grant, Elshenawy’s reported derivative holdings total 376,222 RSUs.
Dudum Andrew reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. Chief Executive Officer Andrew Dudum received a grant of 413,844 Restricted Stock Units. Each RSU represents a contingent right to receive one share of Class A common stock, so the award ties his compensation directly to future share value.
The RSUs vest over four years in substantially equal quarterly installments on March 15, June 15, September 15, and December 15, starting on June 15, 2026. Shares are delivered only as units vest, encouraging long-term service and alignment with shareholders rather than reflecting an open-market purchase.
Okupe Oluyemi reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Financial Officer Oluyemi Okupe received a grant of 300,978 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A common stock.
The RSUs are subject to a service-based vesting schedule over four years. They vest in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, with the first vesting date on June 15, 2026, as long as the service condition is met.
Hims & Hers Health, Inc. announced a strategic shift in its U.S. weight loss business centered on FDA-approved GLP-1 treatments and a new collaboration with Novo Nordisk. The company will prioritize branded, FDA-approved GLP-1 medications and scale back reliance on compounded semaglutide.
In the U.S., Hims & Hers plans to stop advertising compounded GLP-1 offerings and give existing patients the chance to move to FDA-approved drugs when providers find it clinically appropriate. Compounded GLP-1s will be reserved for limited cases where providers determine they are clinically necessary.
Through its agreement with Novo Nordisk, the platform expects to offer Ozempic and Wegovy injections and tablets, expanding dosage and format options for weight loss customers. Concurrently, Novo Nordisk is dismissing its lawsuit against Hims & Hers without prejudice. The company will continue providing provider access, nutrition guidance, and clinical check-ins alongside treatment.